Metformin‐induced mitochondrial function and ABCD 2 up‐regulation in X‐linked adrenoleukodystrophy involves AMP‐activated protein kinase
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
X‐linked adrenoleukodystrophy (X‐ALD) is a progressive neurometabolic disease caused by mutations/deletions in the Abcd1 gene. Similar mutations/deletions in the Abcd1 gene often result in diagonally opposing phenotypes of mild adrenomyeloneuropathy and severe neuroinflammatory cerebral adrenoleukodystrophy (ALD), which suggests involvement of downstream modifier genes. We recently documented the first evidence of loss of AMP‐activated protein kinase α1 (AMPK α1) in ALD patient‐derived cells. Here, we report the novel loss of AMPK α1 in postmortem brain white matter of patients with ALD phenotype. Pharmacological activation of AMPK can rescue the mitochondrial dysfunction and inhibit the pro‐inflammatory response. The FDA approved anti‐diabetic drug Metformin, a well‐known AMPK activator, induces mitochondrial biogenesis and is documented for its anti‐inflammatory role. We observed a dose‐dependent activation of AMPK α1 in metformin‐treated X‐ALD patient‐derived fibroblasts. Metformin also induced mitochondrial oxidative phosphorylation and ATP levels in X‐ALD patient‐derived fibroblasts. Metformin treatment decreased very long chain fatty acid levels and pro‐inflammatory cytokine gene expressions in X‐ALD patient‐derived cells. Abcd2 [adrenoleukodystrophy protein‐related protein] levels were increased in metformin‐treated X‐ALD patient‐derived fibroblasts and Abcd1‐KO mice primary mixed glial cells. Abcd2 induction was AMPK α1‐dependent since metformin failed to induce Abcd2 levels in AMPK α1‐KO mice‐derived primary mixed glial cells. In vivo metformin (100 mg/Kg) in drinking water for 60 days induced Abcd2 levels and mitochondrial oxidative phosphorylation protein levels in the brain and spinal cord of Abcd1‐KO mice. Taken together, these results provide proof‐of‐principle for therapeutic potential of metformin as a useful strategy for correcting the metabolic and inflammatory derangements in X‐ALD by targeting AMPK. imageThere is no effective therapy for inherited peroxisomal disorder X‐linked adrenoleukodystrophy (X‐ALD). We document the therapeutic potential of FDA approved drug, Metformin, for X‐ALD by targeting AMPK. Metformin induced peroxisomal Abcd2 levels in vitro and in vivo. Metformin lowered VLCFA levels, improved mitochondrial function and ameliorated inflammatory gene expression in X‐ALD patient‐derived cells. Metformin‐induced Abcd2 levels were dependent on AMPK α1, a metabolic and anti‐inflammatory gene, recently documented by our laboratory to play a putative role in X‐ALD pathology. Read the Editorial Highlight for this article on page 10.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Currently, approved hematopoietic stem cell transplantation (Shapiro et al. 2000) and the experimental lentiviral gene therapy (Cartier et al. 2009) are attempted only in patients with early stage of cerebral involvement.”
BackgroundMetformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
Metabolism of Inflammation Limited by AMPK and Pseudo-Starvation
O'Neill, L. A. J., & Hardie, D. G. (2013) · Nature · doi:10.1038/nature11862 · Cited by 1,133
Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle
Winder, W. W., Holmes, B. F., Rubink, D. S., Jensen, E. B., Chen, M., & Holloszy, J. O. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.6.2219 · Cited by 709
Mammalian AMP-activated protein kinase subfamily
Stapleton, D., Mitchelhill, K. I., Gao, G., Widmer, J., Michell, B. J., Teh, T., House, C. M., Fernandez, C. S., Cox, T., Witters, L. A., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.611 · Cited by 652 · cited 1×
“The dominant role of AMPKa1in mediating the metformin effect in Abcd1-KO glial cells may be attributed to the higher expression of AMPKa1 subunit than AMPKa2 in brain (Stapleton et al. 1996; Quentin et al. 2011).”
BackgroundKukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T., & Araki, E. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0943 · Cited by 504 · cited 2×
“Furthermore, metformin-induced AMPK activation is associated with increased mitochondrial biogenesis and function (Kukidome et al. 2006; Viollet et al. 2012).”
BackgroundO'Neill, H. M., Maarbjerg, S. J., Crane, J. D., Jeppesen, J., Jørgensen, S. B., Schertzer, J. D., Shyroka, O., Kiens, B., van Denderen, B. J., Tarnopolsky, M. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105062108 · Cited by 406
AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity.
O’Neill, H. M., Holloway, G. P., & Steinberg, G. R. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.019 · Cited by 364
Sanders, M. J., Ali, Z. S., Hegarty, B. D., Heath, R., Snowden, M. A., & Carling, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706543200 · Cited by 347
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329 · cited 2×
“Currently, approved hematopoietic stem cell transplantation (Shapiro et al. 2000) and the experimental lentiviral gene therapy (Cartier et al. 2009) are attempted only in patients with early stage of cerebral involvement.”
BackgroundA mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293
Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Pathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238 · cited 9×
“Metformin induces Abcd2, AMPKa1, and mitochondrial complex subunit levels in vivo in Abcd1-KO mice We next investigated if metformin can induce Abcd2 and AMPKa1 levels in vivo in Abcd1-KO mice CNS tissue.”
BackgroundInfluentialPujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 3×
“Pharmacological over-expression of ABCD2/ABCD3 that have partial sequence similarity to ABCD1, compensates for ABCD1 deficiency in vitro and in vivo, and therefore, has been postulated to be one of the potential therapeutic strategies for X-ALD (Netik et al. 1999; Pujol et al. 2004; Singh et al. 2011).”
BackgroundKung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Kobayashi, T., Shinnoh, N., Kondo, A., & Yamada, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6340 · Cited by 197
Peroxisomal ABC transporters: Structure, function and role in disease
Morita, M., & Imanaka, T. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.009 · Cited by 183 · cited 11×
“ABCD2 has significant sequence similarity with ABCD1/ ALDP, the gene mutated/deleted in X-ALD and therefore, can compensate for ABCD1 loss when over-expressed (Moser 2006).”
BackgroundInfluentialThe role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170 · cited 1×
“ALDP deficiency impairs VLCFA b-oxidation activity and the resultant accumulation of VLCFA (C26 : 0) (Ofman et al. 2010).”
BackgroundNetik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., & Berger, J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.907 · Cited by 148
Pathomechanisms underlying X-adrenoleukodystrophy: A three-hit hypothesis
Singh, I., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00392.x · Cited by 148 · cited 1×
“Glial cells in the brain are the cell types mainly affected in X-ALD (Paintlia et al. 2003; Singh and Pujol 2010).”
BackgroundVascular and cardiac impairments in rats inhaling ozone and diesel exhaust particles
Kodavanti, U. P., Thomas, R., Ledbetter, A. D., Schladweiler, M. C., Shannahan, J. H., Wallenborn, J. G., Lund, A. K., Campen, M. J., Butler, E. O., Gottipolu, R. R., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002386 · Cited by 119
Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients
Jang, J., Kang, H., Kim, H., Kim, J. Y., Huh, Y. J., Kim, D., Yoo, J., Lee, J., Lim, B., Lee, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22486 · Cited by 109 · cited 1×
“Since VLCFA levels correlate with disease severity and inflammatory response in X-ALD in vivo and in in vitro models (Asheuer et al. 2005; Singh et al. 2009; Jang et al. 2011), lowering VLCFA levels may contribute to the overall success of a therapeutic approach in X-ALD.”
BackgroundAsheuer, M., Bieche, I., Laurendeau, I., Moser, A., Hainque, B., Vidaud, M., & Aubourg, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi140 · Cited by 86 · cited 1×
“Since VLCFA levels correlate with disease severity and inflammatory response in X-ALD in vivo and in in vitro models (Asheuer et al. 2005; Singh et al. 2009; Jang et al. 2011), lowering VLCFA levels may contribute to the overall success of a therapeutic approach in X-ALD.”
BackgroundMetformin-Treated Patients With Type 2 Diabetes Have Normal Mitochondrial Complex I Respiration
Larsen, S., Rabøl, R., Hansen, C. N., Madsbad, S., Helge, J. W., & Dela, F. (2012) · Diabetologia · doi:10.1007/s00125-011-2340-0 · Cited by 81 · cited 3×
“In contrast, metformin did not inhibit mitochondrial complex I in vivo in mice or humans (Kane et al. 2010; Larsen et al. 2012; Martin-Montalvo et al. 2013) or induced mitochondrial respiration in AMPK-kinase dead mice (Kristensen et al. 2013).”
BackgroundFunctional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy
Schlüter, A., Espinosa, L., Fourcade, S., Galino, J., López, E., Ilieva, E., Morató, L., Asheuer, M., Cook, T., McLaren, A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr536 · Cited by 72 · cited 2×
“Accumulation of VLCFA is associated with induction of inflammatory response in vivo (Schluter et al. 2012) and in vitro (Singh et al.”
BackgroundFourcade, S., Savary, S., Albet, S., Gauthé, D., Gondcaille, C., Pineau, T., Bellenger, J., Bentejac, M., Holzinger, A., Berger, J., et al. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02249.x · Cited by 70 · cited 1×
“A number of compounds (Fourcade et al. 2001, 2010; Gondcaille et al. 2005; Morato et al. 2013; Singh et al. 2013a,b) have been tested in pre-clinical studies for X-ALD, though none have been able to advance to the clinical settings for reasons of efficacy and/or safety.”
BackgroundKhan, M., Singh, J., Gilg, A. G., Uto, T., & Singh, I. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002329 · Cited by 49 · cited 2×
“Brain white matter of ALD patients shows a clear stratification into normal looking area (NLA) with moderate demyelination to plaque shadow (PLQS) and plaque (PLQ) areas with severe inflammation and demyelination (Khan et al. 2010).”
BackgroundSelf-citationKristensen, J. M., Larsen, S., Helge, J. W., Dela, F., & Wojtaszewski, J. F. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053533 · Cited by 48
Singh, J., Khan, M., & Singh, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.01.004 · Cited by 21 · cited 6×
“Metformin inhibited the expression of iNOS and IL-6 in unstimulated X-ALD patient-derived lymphocytes Accumulation of VLCFA is associated with induction of inflammatory response in vivo (Schluter et al. 2012) and in vitro (Singh et al. 2009, 2011, 2013b; Khan et al. 2010).”
BackgroundInfluentialSelf-citation
Cited by
The changing face of adrenoleukodystrophy
Zhu, J., Eichler, F., Biffi, A., Duncan, C. N., Williams, D. A., & Majzoub, J. A. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa013 · Cited by 78
Pathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms
Parasar, P., Kaur, N., & Singh, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280151 · Cited by 12
Self-citationPoisson, L. M., Kaur, N., Felicella, M. M., & Singh, J. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad144 · Cited by 8
Self-citationKaur, N., & Singh, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041576 · Cited by 4
“The role of inflammation and cytokines in X-ALD has been reported by us and others [12–14, 17, 18 , 36– 38 ].”
InfluentialSelf-citation
Metadata
- Authors
- Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-03-14
- Volume
- 138
- Issue
- 1
- Pages
- 86-100
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2292932642
- Cited by
- 24
- References
- 31
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.